JNJ ▼ -1.4% - Johnson & Johnson $JNJ - RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer 25-OCT-2026 09:45 AM ET